RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $252 from $230 and keeps an Outperform rating on the shares. The company reported “strong” Q3 results and raised guidance, while the stock pull-back since Friday appears “unwarranted”, the analyst tells investors in a research note. Tenet remains RBC;s top hospital pick given its strong fundamentals, the firm added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare’s Q3 2025 Earnings Call Highlights Strong Growth
- Tenet Healthcare: Strong Performance and Positive Outlook Drive Buy Rating
- Tenet Healthcare price target raised to $250 from $200 at Raymond James
- Tenet Healthcare price target raised to $260 from $238 at UBS
- Tenet Healthcare price target raised to $232 from $225 at Morgan Stanley